Arpeggio's technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug's function and guide therapeutic development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/17/20 | $3,200,000 | Seed |
Fifty Years FundersClub TechU Angels Y Combinator | undisclosed |
| 09/07/22 | $17,000,000 | Series A |
ATEM Capital BoxOne Ventures BuildersVC  Fifty Years Formic Ventures FundersClub Longtail Capital Tau Ventures TechU Ventures Tencent Holdings | undisclosed |
